Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inetetamab Regimens in HER2+ Metastatic Breast Cancer
NCT06641544Phase 4Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Oct 2024
- Primary completion
- Dec 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of inetetamab in breast cancer, sponsored by Sun Yat-sen Memorial Hospital. Started Oct 2024; status: recruiting.
02
Drugs
inetetamab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06641544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06641544.